Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 1;34(4):335-341.
doi: 10.1097/CCO.0000000000000854.

Desmoid tumors: who, when and how to treat?

Rabih Mikhael  1 , Myles Smith  2 , Dimitri Tzanis  1 , Sarah Watson  3 , Aisha B Miah  2 , Sylvie Bonvalot  1
Affiliations
Review

Desmoid tumors: who, when and how to treat?

Rabih Mikhael et al. Curr Opin Oncol. .

Abstract

Purpose of review: The objective of this article is to summarize new treatment strategies of desmoid tumors.

Recent findings: Desmoid tumor has an unpredictable evolution that may spontaneously regress or stabilize. A shift toward an initial frontline active surveillance has been acknowledged by experts. Surveillance monitoring should be performed frequently after the diagnosis to avoid missing a significant progression and then spaced in case of stabilization. Treatment is based on significant tumor growth or symptoms. Recent guidelines recommend commencing medical treatment. Kinase inhibitors and cytotoxic agents are the two classes of drugs where studies included progressive desmoid tumors and should be selected to guide medical practice. In a randomized trial, 2 years progression-free survival (PFS) was significantly better in the sorafenib group (81 versus 36% in the placebo group). In another randomized phase 2, 6 months PFS was 83.7% with pazopanib versus 45% with methotrexate and vinblastine. In a retrospective study, including progressive desmoid tumors, methotrexate + vinca alkaloids achieved 75 months median PFS. Cryotherapy is an alternative option in desmoid tumors with compatible locations and tumor sizes. Following medical treatment or cryotherapy failure, superficial sites represent the best indications for surgery in cases of continuous progression. In the event of a contra-indication or failure of medical treatment, in locations where surgery would be mutilating and incomplete, radiotherapy is an effective option.

Summary: Active surveillance with planned imaging has become the first-line management in desmoid tumor.

PubMed Disclaimer

References

    1. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. International agency for research on cancer 2020. WHO classification of tumors series, 5th Edition; vol 3. Available at: https://www.iarc.who.int/news-events/publication-of-the-who-classificati... . [Accessed: 24 August 2021]
    1. Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 2020; 127:96–107.
    1. Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32:1348–1365.
    1. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011; 29:3553–3558.
    1. Bonvalot S, Ternès N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol 2013; 20:4096–4102.

LinkOut - more resources